CAS: 1449040-00-9—Cutting-edge tools for glycobiology research and therapeutic development

At the intersection of glycobiology and biomedicine, glycosylation modification, as the core regulatory mechanism of life processes, is driving the birth of a new generation of diagnostic and therapeutic strategies. Glycan Oxazoline, a type of sugar derivative with a unique structure, has become a key chemical tool for decoding glycosylation codes and developing targeted therapies with its stable cyclic oxazoline core. Among them, compound CBNGO00038, as a representative molecule of this family, is providing indispensable support for scientific research and translational medicine with its precise chemical structure.

Chemical Information

Chemical name: CBNGO00038

Common name: Glycan Oxazoline

Chemical formula: C26H42FNO19

Molecular weight: 691.61 g/mol

CAS number: 1449040-00-9

Structural features

The structural essence of Glycan Oxazoline lies in its unique structure integrating sugar ring and oxygen-nitrogen heterocycle. On this basis, CBNGO00038 introduces modifications such as fluorine atoms, giving it excellent physical and chemical properties:

Stable cyclic core: The oxygen nitrogen heterocycle (Oxazoline) in the molecule is formed by the sugar moiety through C-O and C-N bonding to form a five-membered ring structure. This cyclic system not only enhances the overall metabolic stability, but also reduces non-specific hydrolysis, allowing it to maintain long-term activity in biological environments. Compared with linear glycosides or sugar amines, their cyclic constraints increase conformational rigidity and facilitate specific molecular recognition.

Multifunctional reaction site: The nitrogen atom and adjacent carbon atom on the oxygen-nitrogen heterocycle can serve as the center of electrophilic or nucleophilic reactions, facilitating chemical derivatization, such as efficient coupling with proteins, carriers or probes. At the same time, the introduction of fluorine atoms further regulates electron distribution and lipid solubility, which may optimize cell membrane permeability and pharmacokinetic behavior.

Biomimetic glycosylation template: This structure simulates the characteristics of high-energy intermediates in glycosylation reactions, allowing it to be used as a stable substrate or competitive inhibitor of glycosyltransferases or glycosidases, providing an ideal model for studying enzyme kinetics and mechanisms.

Main applications and advantages

Glycosylation engineering and glycoprotein synthesis

In the development of recombinant protein drugs and vaccines, the glycosylation pattern directly affects the activity, stability and immunogenicity of the product. CBNGO00038 can be used as a key reagent in glycosylation engineering. It can introduce specific sugar chains into specific sites of proteins through chemical or enzymatic approaches to achieve uniform and humanized glycoform modification. Its cyclic structure often shows higher conversion efficiency and specificity in enzymatic reactions, which is helpful for the large-scale production of glycoproteins with therapeutic significance, such as monoclonal antibodies, hormones or cytokines.

Enzyme mechanism research and drug discovery

Glycosyltransferases and glycosidases are important targets for a variety of diseases (such as cancer, infectious diseases, and inherited metabolic disorders). The stable properties of CBNGO00038 make it an excellent tool for exploring the three-dimensional structure, catalytic mechanism and substrate selectivity of these enzymes. Inhibitor design based on its structure can selectively block abnormal glycosylation pathways and provide lead compounds for the development of anti-tumor, anti-viral or anti-inflammatory drugs. In addition, in the study of glucose metabolism diseases, this molecule can be used to track changes in enzyme activity and assist in the discovery of diagnostic biomarkers.

Development of targeted prodrugs and delivery systems

With its modifiable active site and good biocompatibility, the Glycan Oxazoline structure is widely used in prodrug design and smart delivery systems. CBNGO00038 can deliver therapeutic molecules (such as chemotherapeutic drugs, nucleic acids or small molecule inhibitors) to specific cells or tissues through covalent linkage, using sugar recognition receptors (such as lectins) to achieve cell-specific endocytosis. This strategy can significantly improve drug efficacy while reducing systemic toxicity, showing potential in targeted cancer therapy, gene therapy and immune regulation.

Construction of sugar chip and diagnostic platform

In the field of high-throughput screening and clinical diagnosis, CBNGO00038 can be used as the core unit of the glycochip, displaying specific sugar chain structures through immobilization, and used to detect antibodies, lectins or microbial adhesion proteins in serum. Such a platform would be of great value for the early diagnosis of infectious diseases, autoimmune diseases or cancer. Its stable ring structure ensures the signal reliability of the chip during long-term storage and repeated use, and improves detection sensitivity and specificity.

Conclusion

From the exploration of basic glycobiology to the development of innovative drugs, Glycan Oxazoline represents a class of bridge molecules that connect chemical synthesis and life functions. With its precise chemical definition and multi-functional application scenarios, CBNGO00038 not only deepens human understanding of the role of the glycocode in health and disease, but also spawns the birth of new treatment models and diagnostic tools. With the deep integration of glycoscience and precision medicine, such compounds will continue to empower cutting-edge research and develop new solutions from infectious disease prevention and control to chronic disease management.

The above information is provided by the editor of KASONS and is for scientific research only.